Cargando…

Healthcare costs of adverse drug reactions and potentially inappropriate prescribing in older adults: a population-based study

OBJECTIVES: To describe the distribution of costs based on potentially inappropriate prescribing (PIP) and adverse drug reaction (ADR) status in terms of total direct costs and costs caused by ADRs, among older adults. DESIGN: A retrospective cohort study was conducted among older adults, identified...

Descripción completa

Detalles Bibliográficos
Autores principales: Robinson, Eirin Guldsten, Hedna, Khedidja, Hakkarainen, Katja M, Gyllensten, Hanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511550/
https://www.ncbi.nlm.nih.gov/pubmed/36153031
http://dx.doi.org/10.1136/bmjopen-2022-062589
_version_ 1784797664997539840
author Robinson, Eirin Guldsten
Hedna, Khedidja
Hakkarainen, Katja M
Gyllensten, Hanna
author_facet Robinson, Eirin Guldsten
Hedna, Khedidja
Hakkarainen, Katja M
Gyllensten, Hanna
author_sort Robinson, Eirin Guldsten
collection PubMed
description OBJECTIVES: To describe the distribution of costs based on potentially inappropriate prescribing (PIP) and adverse drug reaction (ADR) status in terms of total direct costs and costs caused by ADRs, among older adults. DESIGN: A retrospective cohort study was conducted among older adults, identified from a random sample of the general Swedish population. PIP was identified based on the Screening Tool of Older Persons’ Prescriptions (STOPP) criteria and ADRs were identified using the Howard criteria. Causality between PIP and ADRs was evaluated using Hallas’ criteria. Prevalence-based direct healthcare costs were calculated for the 3-month study period, including the total cost for healthcare and drugs, and the cost caused by ADRs. SETTING: All care levels, including primary care, other outpatient care and inpatient care. PARTICIPANTS: 813 adults ≥65 years. PRIMARY OUTCOME MEASURES: The prevalence and cost of PIP and ADRs. RESULTS: Total direct cost for persons with PIP was approximately twice the total cost of those without PIP (€1958 (€1428–€2616) vs €881 (€817–€1167), p=0.0020). The costs caused by ADRs was 10 times higher among persons with PIP, compared with those without PIP (€270 (€86–€545) vs €27 (€10–€61), p=0.047). For persons with ADRs caused by PIP, total direct costs were €4646 (€2617–€7931). This group represented 8% of the study population and used 25% of the costs. The main cost driver in all studied patient groups was healthcare contacts. CONCLUSIONS: Older persons with PIP and ADRs had high healthcare costs, particularly when ADRs were caused by PIP. Since these costs appear to be substantial, the potential savings by preventing their occurrence may, to a certain degree, cover the added cost of such activities. Further studies should be undertaken to provide further evidence on the costs of PIP, ADRs and ADRs caused by PIP.
format Online
Article
Text
id pubmed-9511550
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-95115502022-09-27 Healthcare costs of adverse drug reactions and potentially inappropriate prescribing in older adults: a population-based study Robinson, Eirin Guldsten Hedna, Khedidja Hakkarainen, Katja M Gyllensten, Hanna BMJ Open Health Economics OBJECTIVES: To describe the distribution of costs based on potentially inappropriate prescribing (PIP) and adverse drug reaction (ADR) status in terms of total direct costs and costs caused by ADRs, among older adults. DESIGN: A retrospective cohort study was conducted among older adults, identified from a random sample of the general Swedish population. PIP was identified based on the Screening Tool of Older Persons’ Prescriptions (STOPP) criteria and ADRs were identified using the Howard criteria. Causality between PIP and ADRs was evaluated using Hallas’ criteria. Prevalence-based direct healthcare costs were calculated for the 3-month study period, including the total cost for healthcare and drugs, and the cost caused by ADRs. SETTING: All care levels, including primary care, other outpatient care and inpatient care. PARTICIPANTS: 813 adults ≥65 years. PRIMARY OUTCOME MEASURES: The prevalence and cost of PIP and ADRs. RESULTS: Total direct cost for persons with PIP was approximately twice the total cost of those without PIP (€1958 (€1428–€2616) vs €881 (€817–€1167), p=0.0020). The costs caused by ADRs was 10 times higher among persons with PIP, compared with those without PIP (€270 (€86–€545) vs €27 (€10–€61), p=0.047). For persons with ADRs caused by PIP, total direct costs were €4646 (€2617–€7931). This group represented 8% of the study population and used 25% of the costs. The main cost driver in all studied patient groups was healthcare contacts. CONCLUSIONS: Older persons with PIP and ADRs had high healthcare costs, particularly when ADRs were caused by PIP. Since these costs appear to be substantial, the potential savings by preventing their occurrence may, to a certain degree, cover the added cost of such activities. Further studies should be undertaken to provide further evidence on the costs of PIP, ADRs and ADRs caused by PIP. BMJ Publishing Group 2022-09-23 /pmc/articles/PMC9511550/ /pubmed/36153031 http://dx.doi.org/10.1136/bmjopen-2022-062589 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Health Economics
Robinson, Eirin Guldsten
Hedna, Khedidja
Hakkarainen, Katja M
Gyllensten, Hanna
Healthcare costs of adverse drug reactions and potentially inappropriate prescribing in older adults: a population-based study
title Healthcare costs of adverse drug reactions and potentially inappropriate prescribing in older adults: a population-based study
title_full Healthcare costs of adverse drug reactions and potentially inappropriate prescribing in older adults: a population-based study
title_fullStr Healthcare costs of adverse drug reactions and potentially inappropriate prescribing in older adults: a population-based study
title_full_unstemmed Healthcare costs of adverse drug reactions and potentially inappropriate prescribing in older adults: a population-based study
title_short Healthcare costs of adverse drug reactions and potentially inappropriate prescribing in older adults: a population-based study
title_sort healthcare costs of adverse drug reactions and potentially inappropriate prescribing in older adults: a population-based study
topic Health Economics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511550/
https://www.ncbi.nlm.nih.gov/pubmed/36153031
http://dx.doi.org/10.1136/bmjopen-2022-062589
work_keys_str_mv AT robinsoneiringuldsten healthcarecostsofadversedrugreactionsandpotentiallyinappropriateprescribinginolderadultsapopulationbasedstudy
AT hednakhedidja healthcarecostsofadversedrugreactionsandpotentiallyinappropriateprescribinginolderadultsapopulationbasedstudy
AT hakkarainenkatjam healthcarecostsofadversedrugreactionsandpotentiallyinappropriateprescribinginolderadultsapopulationbasedstudy
AT gyllenstenhanna healthcarecostsofadversedrugreactionsandpotentiallyinappropriateprescribinginolderadultsapopulationbasedstudy